Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Truist Securities on Regeneron Pharma (REGN): 'Buying opportunity'
September 24, 2024 2:18 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We spoke with Regeneron (REGN, Buy) mgmt today who noted that they have appealed the court's decision as of last night, and... More
Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
September 24, 2024 5:30 AM EDTBaird analyst Brian Skorney reiterated a Neutral rating and $940.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "Incrementally negative on legal update. Regeneron's court battles to protect their 2mg Eylea from biosimilar competition has taken a surprising turn as... More
Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)
September 24, 2024 5:28 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $1,292.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We hosted an investor dinner with Len Schleifer, Co-Founder and CEO, and Ryan Crowe, SVP, IR & Strategic Analysis. They emphasized pipeline opportunities stemming from REGN's science-first approach, including: 1) Ph2 proof-of-concept data for the Factor XI antibody in thrombosis by YE, noting validation per genetic data; 2) Ph1 linvoseltamab+Dupixent data in severe food allergy by YE,... More
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
September 23, 2024 4:00 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,300.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "With today's denial of Regeneron's motion for a preliminary injunction, it's important that we take a step back and highlight the differences in product formulation across Eylea and select biosimilars as it remains unclear how these differences could contribute to differential rulings in the courtroom. Recall, Regeneron received a permanent injunction vs. Mylan back in June.... More
Truist Securities on Regeneron Pharma (REGN): 'view the pressure on stock as an overreaction'
September 23, 2024 3:40 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Regeneron (REGN, Buy) shares were down ~5% (vs. XBI down 2%) in reaction to a Judge denying REGN's preliminary injunction against Amgen's (AMGN, Buy)... More
